Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry

Medical Mycology

Volumn 52, Issue 1, 2014, Pages 90-98

  Morales, Bernardina Penarrieta ^a   Junior, Ivan Neves ^a   Trilles, Luciana ^a   Bertho, Álvaro Luiz ^b   De Vasconcellos Carvalhaes De Oliveira, Raquel ^a   Nishikawa, Marilia Martins ^b   Elias, Mônica Dos Santos ^a   Wanke, Bodo ^a   Dos Santos Lazéra, Márcia ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

antifungal susceptibility; Cryptococcus; flow cytometry

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FLOW CYTOMETRY; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; DRUG EFFECTS; EVALUATION STUDY; MICROBIAL SENSITIVITY TEST; PROCEDURES; TIME;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FLOW CYTOMETRY; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 84942092829     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2013.806827     Document Type: Article

References (34)

1. Davis JA, Horn DL, Marr KA, Fishman JA. Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. Transpl Infect Dis 2009; 11: 432-437.
2. Park BJ, Wannemuehler KA, Marston BJ et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-530.
3. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50: 291-322.
4. Hakim JG, Gangaidzo IT, HeydermanRSetal. ImpactofHIVin-fection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000; 14: 1401-1407.
5. Dixit A, Carroll SF, Qureshi ST. Cryptococcus gattii: an emerging cause of fungal disease in North America. Interdiscip Per-spect Infect Dis 2009; 2009: 840452.
6. Kidd SE, Hagen F, Tscharke RL et al. A rare genotype of Crypto-coccus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA 2004; 101: 17258-17263.
7. Carriconde F, Gilgado F, Arthur I et al. Clonality and α-a recombination in the Australian Cryptococcus gattii VGII population-an emerging outbreak in Australia. PLoS ONE 2011; 6: 16936.
8. Ngamskulrungroj P, Serena C, Gilgado F, Malik R, Meyer W. Global VGIIa isolates are of comparable virulence to the major fatal Cryptococcus gattii Vancouver Island outbreak genotype. Clin Microbiol Infect 2011; 17: 251-258.
9. Fraser JA, Giles SS, Wenink EC et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005; 437: 1360-1364.
10. Trilles L, Lazéra MS, Wanke B et al. Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococ-cus gattii in Brazil. Mem Inst Oswaldo Cruz 2008; 103: 455-462.
11. Santos WRA dos, Meyer W, Wanke B et al. Primary endemic cryptococcosis gattii by molecular type VGII in the state of Pará, Brazil. Mem Inst Oswaldo Cruz 2008; 103: 813-818.
12. Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol 2011; 50: 328-332.
13. Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med 2008; 29: 141-150.
14. Brouwer AE, Teparrukkul P, Rajanuwong A et al. Cerebrospinal fluid HIV-1 viral load during treatment of cryptococcal meningitis. J Acquir Immune Defic Syndr 2010; 53: 668-669.
15. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast, Approved standard, 3rd ed., document M27-A3 (ISBN 1-56238-666-2). Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
16. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast 3rd Informational Suplement document M27-S3 (ISBN 1-56238-667-0). Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
17. Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001; 38: 111-123.
18. Davis BH, Holden JT, Bene MC et al. 2006 Bethesda international consensus recommendations on the flow cytometric im-munophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B Clin Cytom 2007; 72(Suppl. 1): S5-13.
19. Joung YH, Kim HR, Lee MK, Park AJ. Fluconazole susceptibility testing of Candida species by flow cytometry. J Infect 2007; 54: 504-508.
20. Vale-Silva LA, Buchta V. Antifungal susceptibility testing by flow cytometry: is it the future?Mycoses 2006; 49: 261-273.
21. Ramani R, Chaturvedi V. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. An-timicrob Agents Chemother 2000; 44: 2752-2758.
22. Pina-Vaz C, Costa-de-Oliveira S, Rodrigues AG, Espinel-Ingroff A. Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofun-gin by flow cytometry. J Clin Microbiol 2005; 43: 4674-4679.
23. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 1982; 15: 535-537.
24. Aller AI, Martín-Mazuelos E, Gutiérrez MJ et al. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents. J Antimicrob Chemother 2000; 46: 997-1000.
25. Rudensky B, Broidie E, Yinnon AM et al. Rapid flow-cytometric susceptibility testing of Candida species. J Antimicrob Chemother 2005; 55: 106-109.
26. Favalessa OC, Ribeiro LC, Tadano T et al. First description of phenotypic profile and in vitro drug susceptibility of Crypto-coccus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso. Rev Soc Bras Med Trop 2009; 42: 661-665.
27. Nguyen MH, Yu CY. In vitro comparative efficacy of voricona-zole and itraconazole against fluconazole-susceptible and-resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 1998; 42: 471-472.
28. Alvarez-Barrientos A, Arroyo J, Cantón R, Nombela C, Sánchez-Pérez M. Applications of flow cytometry to clinical microbiology. Clin Microbiol Rev 2000; 13: 167-195.
29. Ramani R, Ramani A, Wong SJ. Rapid flow cytometric susceptibility testing of Candida albicans. J Clin Microbiol 1997; 35: 2320-2324.
30. Chaturvedi V, Ramani R, Pfaller MA. Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicans. J Clin Microbiol 2004; 42: 2249-2251.
31. Green L, Petersen B, Steimel L, Haeber P, Current W. Rapid determination of antifungal activity by flow cytometry. J Clin Microbiol 1994; 32: 1088-1091.
32. Ramani R, Chaturvedi V. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. J Antimicrob Chemother 2000; 44: 2752-2758.
33. Joung YH, Kim HR, Lee MK, Park AJ. Fluconazole susceptibility testing of Candida species by flow cytometry. J Infect 2007; 54: 504-508.
34. Yamazumi T, Pfaller MA, Messer SA et al. Characterization of heteroresistance to fluconazole among clinical isolates of Cryp-tococcus neoformans. J Clin Microbiol 2003; 41: 267-272.